RhoA and GPCR mediated transcriptional activation regulates glioblastoma

RhoA 和 GPCR 介导的转录激活调节胶质母细胞瘤

基本信息

  • 批准号:
    10356023
  • 负责人:
  • 金额:
    $ 37.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-02-09 至 2024-01-31
  • 项目状态:
    已结题

项目摘要

Abstract Our past research has provided considerable insight into the signals elicited through G-protein coupled receptors (GPCRs) that activate RhoA on astrocytes and in 1321N1 glioblastoma cells. The pathways regulated through PAR1 and S1P receptors via G12/13 engagement include RhoA activation to increase cell proliferation, survival, and invasion-hallmarks of cancer. Our recent studies demonstrate robust activation of the transcriptional co-activators MRTF-A and YAP through RhoA signaling in glioblastoma cells, and implicate altered gene expression in proliferative and migratory responses. The objective of this proposal is to demonstrate that robust transcriptional gene programs elicited through RhoA signaling are critical to glioblastoma multiforme (GBM) tumor growth and maintenance of glioblastoma stem cells (GSC), with a long term goal of identifying new therapeutic targets for this devastating disease. Aim #1 uses the human 1321N1 glioblastoma cell line to define cellular events and identify changes in specific target genes by which GPCRs and RhoA engage transcriptional pathways that contribute to cancer-relevant cellular responses. S1P- and thrombin-induced proliferation, survival, adhesion, migration, invasion and angiogenesis are assessed in WT and MRTF-A or YAP CRISPR/Cas9 KO cells. Data from RNA seq analysis are used to identify critical regulated genes, and tested for their functional importance in cellular responses. Actions of target genes on, autocrine and transcriptional pathways that amplify response to GPCRs and RhoA are considered. Aim #2 uses patient-derived glioblastoma xenografts (PDX), as a model of glioblastoma stem cells. Several PDX lines will be grown in serum free medium in vitro as neurospheres or adherent cultures and subsequently implanted as orthotopic (brain) xenografts... YAP, MRTF-A, RhoA and their downstream target genes will be knocked down using shRNA and in vitro stem cell markers, cellular responses and in vivo tumor growth assessed. Aim #3 tests the hypothesis that RhoA-mediated transcriptional signaling leads to astrocyte dedifferentiation and gliomagenesis driven by activated Ras). Proof of principle experiments examine dedifferentiation of isolated mouse astrocytes infected with lentiviruses encoding oncogenic Ras and in which molecules in the RhoA signaling pathway are genetically deleted or knocked down with shRNAs. In vivo studies of gliomagenesis are carried out by delivery of oncogenes by lentiviral infection into the hippocampus of GFAP-Cre mice followed by analysis of tumor growth, invasion, and changes in expression of target genes and stem cell markers. The overall findings from these studies should demonstrate that GPCR- and RhoA-mediated transcriptional activation can elicit genetic and functional responses that contribute to dysregulation in glioblastoma, and that RhoA signaling contributes to the oncogenic effect of established GBM tumor drivers. The health-related significance is that these findings could shift the focus of current research and clinical practice from the established disease drivers towards consideration of GPCR- and RhoA-regulated signaling pathways in GBM.
抽象的 我们过去的研究对 G 蛋白偶联引发的信号提供了相当深入的了解 激活星形胶质细胞和 1321N1 胶质母细胞瘤细胞上的 RhoA 的受体 (GPCR)。途径 通过 PAR1 和 S1P 受体通过 Gα12/13 参与进行调节,包括 RhoA 激活以增加细胞 增殖、存活和侵袭——癌症的标志。我们最近的研究表明, 转录共激活因子 MRTF-A 和 YAP 通过胶质母细胞瘤细胞中的 RhoA 信号传导,并暗示 增殖和迁移反应中基因表达的改变。该提案的目的是 证明通过 RhoA 信号传导引发的强大转录基因程序对于 多形性胶质母细胞瘤 (GBM) 肿瘤的生长和胶质母细胞瘤干细胞 (GSC) 的维持,具有长期 长期目标是确定这种毁灭性疾病的新治疗靶点。目标 #1 使用人类 1321N1 胶质母细胞瘤细胞系,用于定义细胞事件并识别特定靶基因的变化,GPCR 可以通过这些变化 RhoA 参与有助于癌症相关细胞反应的转录途径。 S1P-和 在 WT 中评估凝血酶诱导的增殖、存活、粘附、迁移、侵袭和血管生成 和 MRTF-A 或 YAP CRISPR/Cas9 KO 细胞。 RNA seq 分析的数据用于识别关键的 调节基因,并测试它们在细胞反应中的功能重要性。靶基因的作用, 考虑了放大对 GPCR 和 RhoA 反应的自分泌和转录途径。目标#2 使用患者来源的胶质母细胞瘤异种移植物(PDX)作为胶质母细胞瘤干细胞的模型。多条PDX线 将作为神经球或贴壁培养物在体外无血清培养基中生长,然后植入 作为原位(脑)异种移植物...YAP、MRTF-A、RhoA 及其下游靶基因将被敲除 使用 shRNA 和体外干细胞标记物、细胞反应和体内肿瘤生长进行评估。目的 #3 检验 RhoA 介导的转录信号传导导致星形胶质细胞去分化和 由激活的 Ras 驱动的神经胶质瘤发生)。原理实验验证检验分离的去分化 感染编码致癌 Ras 的慢病毒的小鼠星形胶质细胞,其中 RhoA 中的分子 信号通路被基因删除或被 shRNA 敲除。胶质瘤发生的体内研究是 通过慢病毒感染将癌基因递送至 GFAP-Cre 小鼠的海马,然后 分析肿瘤生长、侵袭以及靶基因和干细胞标志物表达的变化。这 这些研究的总体结果表明 GPCR 和 RhoA 介导的转录 激活可以引发遗传和功能反应,导致胶质母细胞瘤失调,并且 RhoA 信号传导有助于已确定的 GBM 肿瘤驱动因素的致癌作用。与健康相关的 重要的是,这些发现可能会将当前研究和临床实践的焦点从 确定了 GBM 中 GPCR 和 RhoA 调节信号通路的疾病驱动因素。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sphingosine 1-phosphate elicits RhoA-dependent proliferation and MRTF-A mediated gene induction in CPCs.
  • DOI:
    10.1016/j.cellsig.2016.04.006
  • 发表时间:
    2016-08
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Castaldi A;Chesini GP;Taylor AE;Sussman MA;Brown JH;Purcell NH
  • 通讯作者:
    Purcell NH
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOAN HELLER BROWN其他文献

JOAN HELLER BROWN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOAN HELLER BROWN', 18)}}的其他基金

Cardiomyocyte CaM kinase II as a driver of cardiac inflammation and remodeling
心肌细胞 CaM 激酶 II 作为心脏炎症和重塑的驱动因素
  • 批准号:
    10308392
  • 财政年份:
    2018
  • 资助金额:
    $ 37.68万
  • 项目类别:
RhoA and GPCR mediated transcriptional activation regulates glioblastoma
RhoA 和 GPCR 介导的转录激活调节胶质母细胞瘤
  • 批准号:
    9905280
  • 财政年份:
    2018
  • 资助金额:
    $ 37.68万
  • 项目类别:
Molecular Mechanism and Therapy for Ocular Melanoma
眼部黑色素瘤的分子机制及治疗
  • 批准号:
    10341047
  • 财政年份:
    2017
  • 资助金额:
    $ 37.68万
  • 项目类别:
Molecular Mechanism and Therapy for Ocular Melanoma
眼部黑色素瘤的分子机制及治疗
  • 批准号:
    10018829
  • 财政年份:
    2017
  • 资助金额:
    $ 37.68万
  • 项目类别:
ISHR 2013 World Congress
ISHR 2013 世界大会
  • 批准号:
    8597882
  • 财政年份:
    2013
  • 资助金额:
    $ 37.68万
  • 项目类别:
2010 Cardiac Regulatory Mechanisms Gordon Research Conference
2010年心脏调节机制戈登研究会议
  • 批准号:
    7905509
  • 财政年份:
    2010
  • 资助金额:
    $ 37.68万
  • 项目类别:
Restoration of Myocardial Healing through G-coupled Protein Receptor Signaling
通过 G 偶联蛋白受体信号转导恢复心肌愈合
  • 批准号:
    8452816
  • 财政年份:
    2006
  • 资助金额:
    $ 37.68万
  • 项目类别:
Cell Biology and Histology
细胞生物学和组织学
  • 批准号:
    8734480
  • 财政年份:
    2006
  • 资助金额:
    $ 37.68万
  • 项目类别:
Restoration of Myocardial Healing through G-coupled Protein Receptor Signaling
通过 G 偶联蛋白受体信号转导恢复心肌愈合
  • 批准号:
    8734475
  • 财政年份:
    2006
  • 资助金额:
    $ 37.68万
  • 项目类别:
Restoration of Myocardial Healing through G-coupled Protein Receptor Signaling
通过 G 偶联蛋白受体信号传导恢复心肌愈合
  • 批准号:
    9324068
  • 财政年份:
    2006
  • 资助金额:
    $ 37.68万
  • 项目类别:

相似海外基金

How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y004841/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.68万
  • 项目类别:
    Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
  • 批准号:
    BB/Y001427/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.68万
  • 项目类别:
    Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y005414/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.68万
  • 项目类别:
    Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
  • 批准号:
    10669829
  • 财政年份:
    2023
  • 资助金额:
    $ 37.68万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10587090
  • 财政年份:
    2023
  • 资助金额:
    $ 37.68万
  • 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
  • 批准号:
    10821599
  • 财政年份:
    2023
  • 资助金额:
    $ 37.68万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10841832
  • 财政年份:
    2023
  • 资助金额:
    $ 37.68万
  • 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
  • 批准号:
    10532480
  • 财政年份:
    2022
  • 资助金额:
    $ 37.68万
  • 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
  • 批准号:
    10741261
  • 财政年份:
    2022
  • 资助金额:
    $ 37.68万
  • 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
  • 批准号:
    10674894
  • 财政年份:
    2022
  • 资助金额:
    $ 37.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了